FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma – Lymphoma News Today
Lymphoma News Today |
FDA to Review Kite's Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin's Lymphoma
Lymphoma News Today Axicabtagene ciloleucel is a CAR (chimeric antigen receptor) T–cell therapy that removes the patient's own T–cells and genetically engineers them to express a receptor that recognizes the CD19 protein, found at the surface of most lymphoma cells. Kite Pharma Inc Receives a Buy from FBR Capital |
